---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-084743"
form_type: "8-K"
ticker: "NWBO"
cik: "0001072379"
company_name: "NORTHWEST BIOTHERAPEUTICS INC"
filed_at: "2026-07-17T23:48:55+00:00"
generated_at: "2026-07-20T10:05:40.678855+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NWBO refutes false rumors of MHRA rejection; MHRA confirms DCVax-L MAA still under review

## Summary
- MHRA confirmed DCVax-L MAA for glioblastoma remains under initial review, not refused, withdrawn, or appealed.
- Company categorically refutes false rumors of MHRA rejection and notes possible stock manipulation.
- Rumors intensified after BNOS Annual Meeting where significant Phase 3 trial data were presented.
- Company continues constructive interactions with MHRA; MAA progressing towards first regulatory decision.

## SEC filing metadata
- accession: 0001104659-26-084743
- form_type: 8-K
- ticker: NWBO
- cik: 0001072379
- company_name: NORTHWEST BIOTHERAPEUTICS INC
- filed_at: 2026-07-17T23:48:55+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1072379/000110465926084743/0001104659-26-084743-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1072379/000110465926084743/tm2620800d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-084743
- JSON: https://secwatch.observer/filing/0001104659-26-084743.json
- Plain text: https://secwatch.observer/filing/0001104659-26-084743.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.